Health, FDA, PRC to probe unethical practices of local pharmaceutical company
MANILA, Philippines — The Department of Health (DOH), the Food and Drug Administration (FDA), and the Professional Regulation Commission (PRC) are joining forces to investigate the alleged unethical practices of a local pharmaceutical company owned by physicians.
A joint committee for investigation (JCI) will be formed by the DOH, FDA, and PRC, with the invitation extended to the Securities and Exchange Commission to participate in the inquiry.
“The JCI aims to streamline due process requirements related to the allegations discussed at the Senate hearing, ensuring the preservation of the medical profession’s integrity while holding accountable those who have breached relevant laws and regulations,” stated the DOH.
The JCI will seek input from professional bodies such as the Philippine Medical Association (PMA), Philippine Pharmacists Association, and Philippine Hospital Association (PHA).
Furthermore, the DOH mentioned that measures are being considered to protect whistleblowers to encourage the sharing of actionable information and evidence.
The investigation was prompted by a Senate hearing on the alleged unethical marketing practices of Bell-Kenz Pharmaceutical Inc., led by physicians. Following the hearing, Health Secretary Ted Herbosa conducted a coordination meeting with regulatory and professional bodies, including the FDA and PRC.
The DOH encourages individuals with pertinent information to contact the FDA Field Regulatory Operations Office to aid in the investigation.
In response, the legal counsel of Bell-Kenz Pharma Inc. defended the company’s practices, emphasizing that there is no unethical behavior in their operations. The company maintains that its prescriptions are based on medical assessments and not influenced by financial gain.
Bell-Kenz’s legal counsel also refuted claims of doctors receiving commissions or extravagant gifts and welcomed any investigation to address the allegations.
Meanwhile, the Senate Blue Ribbon committee is poised to take over the investigation on pharmaceutical companies offering incentives to doctors for prescribing their medicines, shifting the probe from the Senate committee on health as agreed upon by senators during a caucus.
